Pfizer Inc. Files 8-K Report

Ticker: PFE · Form: 8-K · Filed: 2024-12-17T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: PFE

TL;DR

Pfizer filed an 8-K on 12/17/24, mostly standard disclosures.

AI Summary

On December 17, 2024, Pfizer Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific new financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates that Pfizer is providing updated information to the SEC, which could include financial disclosures or other material events relevant to investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for disclosures and exhibits, not indicating any immediate negative or positive material events.

Key Players & Entities

Pfizer Inc. (company) — Registrant
December 17, 2024 (date) — Date of report
Delaware (jurisdiction) — State of incorporation
13-5315170 (identification_number) — I.R.S. Employer Identification No.
66 Hudson Boulevard East (address) — Principal executive offices
New York, New York (location) — Principal executive offices
10001-2192 (zip_code) — Principal executive offices
( 212 ) 733-2323 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing by Pfizer Inc.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

On what date was this 8-K report filed?

This 8-K report was filed on December 17, 2024.

In which state was Pfizer Inc. incorporated?

Pfizer Inc. was incorporated in Delaware.

What is the principal executive office address for Pfizer Inc.?

The principal executive office address is 66 Hudson Boulevard East, New York, New York, 10001-2192.

What is Pfizer Inc.'s telephone number as listed in the filing?

Pfizer Inc.'s telephone number is (212) 733-2323.

From the Filing

0000078003-24-000195.txt : 20241217 0000078003-24-000195.hdr.sgml : 20241217 20241217074710 ACCESSION NUMBER: 0000078003-24-000195 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241217 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241217 DATE AS OF CHANGE: 20241217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 241553672 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20241217.htm PFIZER 8-K DECEMBER 17, 2024 pfe-20241217 0000078003 false 0000078003 2024-12-17 2024-12-17 0000078003 us-gaap:CommonStockMember 2024-12-17 2024-12-17 0000078003 pfe:NotesDue20271.000Member 2024-12-17 2024-12-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2024 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 7.01.     Regulation FD Disclosure. On December 17, 2024, Pfizer Inc. issued a press release that provided its full-year 2025 guidance and reaffirmed its full-year 2024 financial guidance. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information furnished pursuant to this “Item 7.01 – Regulation FD Disclosure”, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the l